Perrigo Company plc Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net
Perrigo Company plc (PRGO) reported Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net of -$1.50 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-27.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet · last filed 2019-02-27
- Perrigo Company plc adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2016 was -$1.50M.
- Perrigo Company plc adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2015 was $7.00M, a 14.63% decline from fiscal 2014.
- Perrigo Company plc adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2014 was $8.20M, a 52.05% decline from fiscal 2013.
- Perrigo Company plc adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2013 was $17.10M, a 16.33% increase from fiscal 2012.
| Period end | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 6 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month |
|---|---|---|
| 2016-12-31 | -$1.50M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $3.30M 10-K · filed 2018-03-01 | |
| 2015-06-27 | $7.00M 10-K · filed 2018-03-01 | |
| 2014-06-28 | $8.20M 10-K · filed 2017-05-22 | |
| 2013-06-29 | $17.10M 10-KT · filed 2016-02-25 | |
| 2012-06-30 | $14.70M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |